Genomic & Biopharma News

After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.
Fierce Biotech, 2020-01-17 12:16:06

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County.
ORB Company News, 2016-12-02 15:35:33

Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
PharmaTimes, 2020-01-17 11:46:33

Government health commitments just a ‘pipedream’
The plans were “ambitions”, and primary care is not being given the time, support and funding it needs.
PharmaTimes, 2020-01-17 11:42:31

Employers’ dream of controlling health costs turns to workers’ sleep
Charlie Blakey had a sense he was sleeping poorly since he often would wake up tired and hear from his wife how loudly he breathed during the night.
News Medical Life Sciences, 2020-01-17 11:06:37

Vitrakvi deemed ‘not cost-effective’ by NICE
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
PharmaTimes, 2020-01-17 10:50:49

Electronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach

ORB Company News, 2016-12-02 21:24:27

Sepsis death rates ‘double’ previous figures
The new study included data from low- and middle-income countries, bringing the estimated total from 5.3 million deaths to 11 million.
PharmaTimes, 2020-01-17 10:11:26

FiercePharmaAsia—Astellas' cell therapy deal; Takeda's €398M tax bill; Lilly-shared PD-1 in NSCLC
Astellas teamed up with Adaptimmune to develop CAR-T and TCR therapies. Takeda faces a surprising Irish tax bill linked to the Shire breakup fee AbbVie paid years ago. Innovent's Eli Lilly-partnered PD-1, Tyvyt, hits its goal in a phase 3 frontline non-small cell lung cancer trial in China. And more.
Fierce Pharma, 2020-01-17 09:36:03

Frazier closes $617M life sciences fund, creating scope for bigger bets
Frazier Healthcare Partners has closed a $617 million life sciences fund, setting it up to place another set of bets spanning from company creation through public investments. Two-thirds of Frazier Life Sciences X will go into seed and series A rounds. 
Fierce Biotech, 2020-01-17 09:17:32

15 percent of people in the US are physically inactive, CDC report says
The new year may have motivated people to jot down their fitness goals, but a new country-wide map of inactivity in the Centers for Disease Control and Prevention (CDC), may show that this might not be feasible unless people start to become more physically active.
News Medical Life Sciences, 2020-01-17 05:08:32